Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q05823

UPID:
RN5A_HUMAN

ALTERNATIVE NAMES:
Ribonuclease 4; Ribonuclease L

ALTERNATIVE UPACC:
Q05823; Q5W0L2; Q6AI46

BACKGROUND:
The 2-5A-dependent ribonuclease, known alternatively as Ribonuclease L, is integral to the body's defense against viral infections. It operates by cleaving viral RNAs, inhibiting protein synthesis, and triggering apoptosis in infected cells. Additionally, it plays a role in mRNA turnover and may induce autophagy under stress conditions, highlighting its multifaceted role in cellular responses to viral threats.

THERAPEUTIC SIGNIFICANCE:
Ribonuclease L's involvement in hereditary prostate cancer underscores its potential as a target for therapeutic intervention. By delving deeper into the functions and mechanisms of Ribonuclease L, researchers can unlock new pathways for treating viral diseases and hereditary cancer, offering hope for advancements in medical treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.